Lead Product(s): Autologous pancreatic islets cells
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Kyslecel
Highest Development Status: Approved Product Type: Cell and Gene therapy
Deal Size: $16.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Following closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well.